Impact of Repeated Doses of Subcutaneous Esketamine on Acute Dissociative Symptoms in Treatment-Resistant Depression
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Impact of Repeated Doses of Subcutaneous Esketamine on Acute Dissociative Symptoms in Treatment-Resistant Depression
Authors
Keywords
-
Journal
Pharmaceuticals
Volume 16, Issue 1, Pages 31
Publisher
MDPI AG
Online
2022-12-27
DOI
10.3390/ph16010031
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Repeated subcutaneous esketamine for treatment-resistant depression: Impact of the degree of treatment resistance and anxiety comorbidity
- (2021) Ana C Lucchese et al. JOURNAL OF PSYCHOPHARMACOLOGY
- Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program
- (2020) Teodora Doherty et al. CNS DRUGS
- Effects of subcutaneous esketamine on blood pressure and heart rate in treatment-resistant depression
- (2020) Lorena Catarina Del Sant et al. JOURNAL OF PSYCHOPHARMACOLOGY
- A simplified 6-Item clinician administered dissociative symptom scale (CADSS-6) for monitoring dissociative effects of sub-anesthetic ketamine infusions
- (2020) Nelson B. Rodrigues et al. JOURNAL OF AFFECTIVE DISORDERS
- Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study
- (2019) Vanina Popova et al. AMERICAN JOURNAL OF PSYCHIATRY
- Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1)
- (2019) Maggie Fedgchin et al. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
- Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression
- (2019) Ella J. Daly et al. JAMA Psychiatry
- Interaction of Sex and Age on the Dissociative Effects of Ketamine Action in Young Healthy Participants
- (2019) B. Derntl et al. Frontiers in Neuroscience
- Efficacy and safety of adjunctive therapy using esketamine or racemic ketamine for adult treatment-resistant depression: A randomized, double-blind, non-inferiority study
- (2019) Fernanda S. Correia-Melo et al. JOURNAL OF AFFECTIVE DISORDERS
- Comprehensive assessment of side effects associated with a single dose of ketamine in treatment-resistant depression
- (2019) Elia E. Acevedo-Diaz et al. JOURNAL OF AFFECTIVE DISORDERS
- Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study
- (2018) Carla M. Canuso et al. AMERICAN JOURNAL OF PSYCHIATRY
- Features of dissociation differentially predict antidepressant response to ketamine in treatment-resistant depression
- (2018) Mark J. Niciu et al. JOURNAL OF AFFECTIVE DISORDERS
- Acute psychoactive effects of intravenous ketamine during treatment of mood disorders: Analysis of the Clinician Administered Dissociative State Scale
- (2018) Gerrit I. van Schalkwyk et al. JOURNAL OF AFFECTIVE DISORDERS
- Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression
- (2018) Ella J. Daly et al. JAMA Psychiatry
- Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD)
- (2018) Maurizio Fava et al. MOLECULAR PSYCHIATRY
- Ketamine’s dose-related effects on anxiety symptoms in patients with treatment refractory anxiety disorders
- (2017) Paul Glue et al. JOURNAL OF PSYCHOPHARMACOLOGY
- Placebo-controlled pilot trial testing dose titration and intravenous, intramuscular and subcutaneous routes for ketamine in depression
- (2016) C. K. Loo et al. ACTA PSYCHIATRICA SCANDINAVICA
- Intravenous Esketamine in Adult Treatment-Resistant Depression: A Double-Blind, Double-Randomization, Placebo-Controlled Study
- (2016) Jaskaran B. Singh et al. BIOLOGICAL PSYCHIATRY
- Long-Lasting Effects of a Single Subcutaneous Dose of Ketamine for Treating Melancholic Depression: A Case Report
- (2014) Veronica Gálvez et al. BIOLOGICAL PSYCHIATRY
- Do the dissociative side effects of ketamine mediate its antidepressant effects?
- (2014) David A. Luckenbaugh et al. JOURNAL OF AFFECTIVE DISORDERS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started